Metastatic growth in distant organs is the major cause of cancer mortality. The development of metastasis is a multistage process with several rate-limiting steps 1 . Although dissemination of tumour cells seems to be an early and frequent event 2 , the successful initiation of metastatic growth, a process termed 'metastatic colonization', is inefficient for many cancer types and is accomplished only by a minority of cancer cells that reach distant sites 3, 4 . Prevalent target sites are characteristic of many tumour entities 5 , suggesting that inadequate support by distant tissues contributes to the inefficiency of the metastatic process. Here we show that a small population of cancer stem cells is critical for metastatic colonization, that is, the initial expansion of cancer cells at the secondary site, and that stromal niche signals are crucial to this expansion process. We find that periostin (POSTN), a component of the extracellular matrix, is expressed by fibroblasts in the normal tissue and in the stroma of the primary tumour. Infiltrating tumour cells need to induce stromal POSTN expression in the secondary target organ (in this case lung) to initiate colonization. POSTN is required to allow cancer stem cell maintenance, and blocking its function prevents metastasis. POSTN recruits Wnt ligands and thereby increases Wnt signalling in cancer stem cells. We suggest that the education of stromal cells by infiltrating tumour cells is an important step in metastatic colonization and that preventing de novo niche formation may be a novel strategy for the treatment of metastatic disease.
1
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We aimed to explore limiting factors that determine metastatic success using the MMTV-PyMT mouse breast cancer model, which spontaneously metastasizes to the lungs 6 . We reasoned that the recently identified cancer stem cells (CSCs, also called tumour-initiating cells), a subset of cancer cells that allow long-term tumour growth and are thought to be responsible for remissions 7, 8 , might also be relevant to the development of metastatic disease ( Supplementary Fig. 1 ). We measured the relative size of the population of CSCs from primary MMTV-PyMT tumours and their pulmonary metastases using the previously established markers CD90 and CD24, which label a subset of the CD24
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1 CD49f hi population used earlier to isolate CSCs and normal mammary gland stem cells [9] [10] [11] [12] [13] (Supplementary Fig. 2 ). This CSC subset accounts for 3 6 2.1% (s.d.) of all tumour cells from both primary tumours and metastases (Fig. 1a) . When CD90
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1 CSCs or CD90
1
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1 -depleted non-CSCs are separately isolated from GFP 1 tumours and directly introduced into mice through tail vein injection (GFP, green fluorescent protein), only the CSC population is able to produce lung metastases (Fig. 1b) . Moreover, CD90
1
CD24
1 cells isolated subsequently from pulmonary metastases are again the only tumour cell population that efficiently initiates secondary metastases (Fig. 1c) . This is not due to differences in the extravasation capabilities of CSCs and non-CSCs ( Supplementary  Fig. 3 ).
In time course experiments, the relative size of the CSC population changes drastically during metastatic colonization. When injecting unfractionated tumour cells, the total number of tumour cells in the lung declines rapidly within the first 7 d after seeding 14 ( Fig. 1d and Supplementary Fig. 4) . Notably, the relative amount of CSCs transiently increases within the first and second weeks to more than 20%. This is due to selective expansion of the stem cell population as a result of their proliferation rate increasing over sixfold relative to the primary tumour in this early phase of metastatic colonization (as measured by BrdU incorporation; Fig. 1e and Supplementary Fig. 5 ). By contrast, non-CSCs show reduced proliferation 7 d after injection and, notably, fail to generate CSCs ( Fig. 1e and Supplementary Fig. 6 ). Consequently, only CSCs are able to form metastatic colonies, and non-CSCs remain as single cells (Fig. 1f) . Together, this demonstrates that selective expansion of CSCs is responsible for the initiation of metastasis.
The number of injected CSCs evidently exceeds the number of metastatic nodules, indicating that additional factors restrict successful metastatic colonization. Stem cells are suspected to rely on signals from their stromal environment, such as localized growth factors that can affect stem cell maintenance and proliferation [15] [16] [17] . We identified Postn as a stromal factor of normal stem cell niches and the metastatic niche (Supplementary Methods). Postn encodes for periostin, which becomes incorporated in the extracellular matrix 18 and has a role in bone, tooth and heart development and function [19] [20] [21] . Its expression is downregulated in the adult except in niches in direct contact with tissue-specific stem cells in mammary gland, bone, skin and intestine ( Fig. 2a and Supplementary Figs 7 and 8 ). In tumours, POSTN is produced by stromal aSMA 1 VIM 1 (aSMA also known as ACTA2) fibroblasts according to RNA in situ hybridization, immunostaining and quantitative PCR (Fig. 2b-h) . Notably, POSTN expression is induced in the lung stroma by infiltrating cancer cells (Fig. 2d) , but does not occur in the alveolar lung tissue of tumour-bearing but metastasis-free animals ( Supplementary Fig. 8 ). Human breast cancer patients show induction of stromal POSTN expression in 75% of lymph node metastases (Fig. 2i, j and Supplementary Fig. 9 ). Whereas POSTNdeficient mice maintain normal mammary gland development (Supplementary Figs 10-12), MMTV-PyMT Postn 2/2 breast cancers show a dramatic decrease in the number and size of pulmonary metastases, to less than 10% of controls, despite unaltered primary tumour size and morphology (n 5 37, P , 0.003; Fig. 3a-d Supplementary  Fig. 18 ), indicating that stromal production of POSTN determines metastatic efficiency.
In searching for tumour-derived factors that can induce stromal POSTN, in silico promoter analysis predicted regulation mediated by SMAD, NF-kB and LEF/TCF. Primary lung fibroblasts upregulate POSTN in response to TGF-b3 and TGF-b2, but are not responsive to BMP4, Wnt3A, Wnt5A or TNF-a (Fig. 3e, Supplementary Fig. 19 and data not shown). Co-culture experiments revealed that tumour cells are sufficient to trigger POSTN production ( Supplementary Fig. 20) . Notably, CSCs and non-CSCs both produce high levels of TGF-b3 ( Supplementary Fig. 21 ), and blocking the action of TGF-b3 by expression of a secreted decoy receptor 22 (TGFbR2DTM; see Methods) in tumour cells blocks POSTN expression and prevents metastasis formation ( Fig. 3f and Supplementary Fig. 22 ) in line with earlier results 23 .
Together, these experiments demonstrate that infiltrating tumour cells need to educate the host stroma of the target organ to support metastasis initiation.
Even small metastatic colonies are strongly diminished in POSTNdeficient animals ( Supplementary Fig. 23 ). Having shown that metastatic colonization depends on cancer stem cells, we went on to assess a potential role of POSTN in stem cell maintenance. Growth under conditions of ultralow attachment has been used to study CSCs in vitro 24 . Surprisingly, establishment of such cancer stem cell cultures is not possible using POSTN-deficient tumours ( Fig. 3g-j ; n 5 16; compare with Supplementary Fig. 24 , which shows unaltered cell survival in standard two-dimensional culture). In wild-type tumour spheres, POSTN is expressed by tumour-derived, stromal fibroblasts ( Supplementary Fig. 25 ). Adding periostin protein to the mutant tumour cells rescues sphere formation (Fig. 3j) . Conversely, a blocking antibody targeting POSTN prevents maintenance of wild-type cancer stem cells ( Supplementary Fig. 30 ), but affects neither cellular survival nor growth per se ( Supplementary Figs 26 and 27 ). Furthermore, CSCs fail to proliferate when co-cultured with POSTN-mutant, pulmonary fibroblasts (Fig. 3k) . In lung metastases, we observe a preferential localization of CD90
1 CSCs adjacent to stromal niches (Fig. 3l) , whereas lung metastases in POSTN-deficient animals show a reduction in the size of the CSC population (Fig. 3m) . Thus, POSTN is an essential niche factor that supports CSC growth during metastatic colonization.
To gain insight into how POSTN is related to the mechanisms that control stem cell maintenance, we characterized the interactome of POSTN by tandem affinity purification (TAP)-tag enrichment and 
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tandem mass spectrometry (Supplementary Methods), and this pointed to binding of POSTN to Wnt ligands 25 . Using TAP-tag pull-downs, we confirmed interaction between POSTN and Wnt1 and Wnt3A, but found that a known inhibitory ligand of the pathway, DKK1, does not associate with POSTN (Fig. 4a, b and Supplementary Fig. 28 ). The interaction between POSTN and Wnt ligands boosts Wnt signalling activity as measured by LRP6 phosphorylation and reporter assays using Wnt1, Wnt2 and Wnt6 (Fig. 4c, d ). The Wnt pathway is known to control stem cell maintenance in a variety of tissues, including mammary gland 26 and tumours 8, 27, 28 . Indeed, addition of Wnt3A can rescue in vitro stem cell expansion in the absence of POSTN (Supplementary Figs 30 and 31) . Furthermore, we find Wnt signalling activity to be concentrated in the CSC population in vivo as analysed by FACS (Fig. 4e, f) . Here, we use a lentiviral reporter that allows Wntinducible GFP expression and constitutive labelling of individual reporter-containing cells by human CD2 (Supplementary Fig. 29 ). Wnt signalling activity in metastases is abrogated in the absence of POSTN ( Fig. 4g ; see Supplementary Fig. 29 for Wnt activity in tumour spheres). Similarly, we detect higher levels of the general Wnt target gene Axin2 in metastases in wild-type hosts than in mutant hosts (Fig. 4h, i) . Remarkably, metastasis of Wnt-driven breast cancer proves to be independent of stromal POSTN (Fig. 4j) . Thus, POSTN acts as a niche component that can promote stem cell maintenance and metastatic colonization by augmenting Wnt signalling (Supplementary Fig. 1 ).
Thus, instrumental factors that contribute to the inefficiency of the metastatic process are the low abundance of CSCs, which are required to initiate growth at the secondary site, and incompatibilities with 'foreign' niches, which necessitate education of the target organ to resemble the primary microenvironment. Periostin is an essential component of this CSC-supportive niche and needs to be induced in the lung stroma by infiltrating tumour cells. Together with a recent report that implicated tumour-cell-derived tenascin C in breast cancer metastasis, these examples demonstrate an essential role for single proteins of the extracellular matrix in metastatic colonization 29, 30 . Surprisingly, POSTN deficiency affects neither normal mammary gland development nor tumour formation or the relative size of the CSC population at the primary site ( Supplementary Fig. 32 ). This may be due to a greater complexity and redundancy in the primary niche, such that the loss of a single factor can be tolerated. By contrast, loss of only one important factor, such as POSTN, prevents metastatic colonization in the presumably less supportive and less complex secondary site. Accordingly, the early phase of metastasis can be anticipated to be particularly sensitive to therapeutic intervention because the dependence of cancer cells on niche signals is probably highest in that phase. Targeting this metastatic niche promises to be less sensitive to rapid genetic changes in cancer cells and may not only prevent metastatic colonization but may also interfere with the survival of disseminated, dormant cancer cells.
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METHODS
Mouse work. The design of the POSTN targeting vector is shown in Supplementary Fig. 10 . E14.1 129/Ola ES cells were used for targeting and were injected into C57Bl6 blastocysts. The POSTN mutant allele was then backcrossed onto the FVB background for at least eight generations. The MMTV-PyMT 31 , MMTV-Wnt1 32 and the ACT-GFP 33 mouse strains have been described previously. All used strains were backcrossed onto FVB for ten generations except for the Nude allele, which was used on a NMRI background. For tumour cell transplantations, Nude or Rag1 2/2 mice were used when tumour cells expressed GFP or had been modified by lentiviral vectors. In general, we did not observe major differences in these different strains with respect to cancer stem cell phenotype, tumour take rate or metastasis number, except for an overall faster growth in Rag1 2/2 versus Nude versus wild type. For tail vein injections, tumour cells were resuspended in 100 ml of PBS. For orthotopic transplantations, tumour cells were resuspended in 50 ml growth-factor-reduced matrigel (BD Biosciences) and transplanted into a small pocket within the fourth mammary fat pad. All animal procedures were performed in accordance with the Swiss legislation on animal experimentation. Antibodies. We used TER119, CD24, CD29, CD34, CD45 and CD90.1 (eBioscience); CD31 and GFP (Invitrogen); Cytokeratin 8, POSTN, AXIN2 and Wnt1 (Abcam); POSTN (Adipogen); Cytokeratin 14 (Covance); GATA-3 and PyMT (Santa Cruz Biotechnology); aSMA (Sigma); VIM (Lifespan Biosciences); and BrdU (BD Pharmingen and ImmunologicalsDirect). The antibody against human CD2 was a kind gift by Professor Werner Held (Ludwig Center for Cancer Research, Lausanne). Tumour and metastasis evaluation. For the quantification of spontaneous micrometastasis, lungs were completely sectioned and HE stained, and the size and the number of metastatic nodules were analysed by microscopy. Quantification of lung metastases derived from GFP 1 tumour cells was performed by fluorescent microscopy (Leica M205 FA stereomicroscope) or by FACS analysis of cell preparations from total lungs. All statistical evaluation used a homoscedastic Student's t-test with a two-tailed distribution.
For expression of a secreted TGFb decoy receptor (TGFbR2DTM), tumour cells were transduced with lentiviral vectors expressing the extracellular domain (amino acids 1-185) of murine TGFbR2 (NM_009371.3) under the control of a murine phosphoglycerate kinase (PGK) promoter, and metastases were scored as described above following tail vein injection of transduced tumour cells. Tumour cell isolation. Tumours or lungs containing pulmonary metastases were minced with a razor blade and digested with a mixture of DNase and Liberase (Roche Diagnostics). On enzymatic digestion, samples were passed through a 100-mm filter and washed once in growth medium (DMEM/F12 with 2% FBS, 20 ng ml 21 EGF, 10 mg ml 21 insulin; Invitrogen) and twice in PBS. Cells were then directly used for FACS staining and analysed in a Cyan ADP flow cytometer (Beckman Coulter) or sorted with a custom-built FACSAria II (Beckton Dickinson). For tail vein injection, cells were plated overnight on collagen. In the experiments evaluating the metastasis initiation potential of CSCs versus non-CSCs, we were able to prepare and inject higher cell numbers from metastases than from primary tumours, where larger necrotic areas limit the obtainable cell amounts. In both settings, only CSCs were able to give rise to pulmonary metastases, but this experimental setting is unsuitable for a direct comparison of the metastatic potential of CSCs isolated from primary tumours with that of those isolated from metastases. In the extravasation experiments, we performed several pilot experiments perfusing the lungs before dissection to distinguish cells trapped inside capillaries from those that successfully extravasated. Perfusion was done with Ringer's buffer through the right ventricle for 5-10 min. Tumour mammosphere cultures. Sphere cultures were established from total tumour cell preparations. After dissociation, tumour cells were plated on collagen overnight, trypsinized and plated in 100 ml of sphere media (DMEM/F12 with B27, 20 ng ml 21 EGF, 20 ng ml 21 FGF and 4 mg ml 21 heparin) into 96-well, low-attachment plates (Constar) at a concentration of (1-3) 3 10 4 cells per well. For the anti-POSTN blocking antibody assay, half of the culture medium was replaced by hybridoma supernatant. Secondary mammosphere culture was performed by collecting the spheres through gentle centrifugation (130g) followed by enzymatic (10 min in 0.05% trypsin-EDTA at 37 uC) and mechanical dissociation using a 25G needle. Immunostainings were performed as whole mounts of PFA-fixed and 0.1% Triton-X100-permeabilized spheres and were analysed by confocal microscopy. Identification of POSTN as a niche-expressed factor. To identify nicheexpressed factors, we performed microarray RNA profiling studies where we analysed laser-capture microdissected material from normal stem cells together with their adjacent stroma. This was compared with laser-capture microdissected material isolated from differentiated cells together with their adjacent stroma from the same tissue (data not shown). Skin and intestine contain stem cells in morphologically distinct structures (the bulge in the skin, the crypt in the intestine). On the basis of these profiles (accessible through GEO GSE31730 and 8818), we evaluated potential niche localization of candidate genes by RNA in situ hybridization and immunofluorescence analysis (Fig. 2a, Supplementary Fig. 7 and data not shown). Moreover, we profiled the candidate genes by quantitative PCR with reverse transcription and performed RNA in situ hybridization in other tissues, in tumours and in metastases (data not shown). This identified POSTN as a stromal marker in primary murine breast cancer and its metastases (Fig. 2) . Immunodetection and in situ hybridization. Immunostaining was performed on 7-mm OCT-or gelatin-embedded (to maintain GFP signals) frozen sections permeabilized with 0.1% Triton-X100 or on 5-mm paraffin sections using antigen retrieval for 20 min in boiling, 10 mM citric acid, pH 6.0. For BrdU immunostaining, an additional incubation period of 10 min in 2 N HCl was performed. For immunohistochemistry, endogenous peroxidases were blocked by incubation with 0.6% H 2 O 2 in methanol. After incubation with the indicated antibodies, secondary fluorescently labelled antibodies Alexa Fluor 488, 567 and 647 (Molecular Probes, Invitrogen) or HRP-conjugated secondary antibodies were used to reveal the primary antibodies. For immunohistochemistry, Dako Envision 1 was used together with diaminobenzidine tablets (Sigma) to detect HRP. Fluorescent images were made with an automated upright microscope system (DM5500, Leica) or an LSM700 upright or inverted confocal microscope (Zeiss). Light images were made with an AX70 widefield microscope (Olympus). Figures were generated with PHOTOSHOP (Adobe Systems) and CYTOSKETCH (CytoCode).
In situ hybridizations were performed on paraffin sections permeabilized by proteinase K digestion using DIG-labelled (Roche), antisense transcripts of the mouse POSTN complementary DNA. After hybridization, section were washed in 50% formamide, 35 SSC (0.75 M NaCl, 85 mM sodium citrate, pH 7.0) and 0.1% Tween at 70 uC, and non-specifically bound probe was digested by RnaseA treatment, followed by extensive washing in 50% formamide, 32 SSC and 0.1% Tween at 65 uC. The DIG label was detected by an anti-DIG Fab (Roche) coupled to alkaline phosphatase using FAST NBT/BCIP (Sigma). Western blot. Protein was extracted with complete RIPA buffer, separated by electrophoresis, transferred to PVDF membranes, blocked with 5% dry milk or BSA and incubated overnight with primary antibodies. Immunoreactive bands were visualized using HRP-conjugated secondary antibodies (Promega) and the detection reagent SuperSignal West Cheminoluminiscent Substrate (Thermo Scientific). Real-time RT-PCR. RNA was prepared using a miniRNA or microRNA kit (Qiagen) from FACS-isolated primary cells. Complementary DNAs were generated using oligo-T priming and quantitative PCR was performed in a LightCycler (Roche) or a StepOnePlus thermocycler (Applied Biosystems) using the Power SYBR green PCR Master Mix (Applied Biosystems) and the primers aatgctgccctggc tatatg and gcatgacccttttccttcaa (POSTN); agcgcagacacaacccatag and gggttctgccca catagtacaag (TGF-b3); and caagctcatttcctggtatgacaat and gttgggatagggcctctcttg (GAPDH). Periostin monoclonal antibody production. In collaboration with Adipogen, we injected Postn 2/2 mice with purified human POSTN protein. Hybridomas were generated and tested for antibody production by ELISA. Antibodies were selected for their ability to recognize POSTN and for their ability to block tumour mammosphere formation in vitro. Periostin interactome and pull-downs. Freshly isolated tumour cells were grown under mammosphere conditions in the presence of purified, polyHis-tagged and streptavidin binding peptide (SBP)-tagged POSTN protein ( Supplementary Fig. 28 ) for 72 h. Then proteins were crosslinked by 1 mM DTSSP (Pierce) for 10 min and solubilized by DDM and SDS (Anatrace). Protein purification was achieved by two successive affinity purification steps using the SBP and the polyHis tags and elution by biotin and imidazole, respectively. After elution, the crosslink was released by DTT treatment, the resulting protein mixture was trypsin-digested and peptides were identified by one-dimensional nano-liquid chromatography tandem mass spectrometry. Among the POSTN-attached proteins, we found Wnt6 to be a potential interactor. Because these experiments involved crosslinkers, we consider these results to be preliminary unless confirmed by independent experiments. For Wnt6, an interaction with POSTN could not be validated owing to a lack of Wnt6 antibodies and a suitable expression system for Wnt6. Nevertheless, this preliminary finding prompted us to test directly for interactions of POSTN with other Wnt ligands where the necessary tools are available. For these pull-downs, cDNAs encoding Wnt1, HA-tagged Wnt3A, DKK1 and SBP/His-tagged POSTN ( Supplementary Fig. 28 ) or SBP/His-tagged mouse immunoglobulin-G heavy chain (as a control) were transfected separately into 293T cells. Cells secreting POSTN or immunoglobulin-G and cells producing Wnt or DKK were mixed after one day and collected for pull-downs after three additional days. Without the use of crosslinkers, POSTN-interacting proteins were enriched by the SBP/His tag as described above using NP40 as detergent. Western blot was performed for identification of the pulled-down proteins.
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Wnt reporter activity. HEK293T cells were transduced with a lentiviral vector containing a LEF/TCF-responsive luciferase reporter consisting of a minimal promoter and 20 copies of the LEF/TCF consensus site or a control construct in which the LEF/TCF sites had been mutated 34 . These stable Wnt reporter cell lines were then transiently transfected with a POSTN expression vector before these cells were mixed with transiently transfected HEK293T or COS7 cells (the latter for Wnt6 expression) producing Wnt1, Wnt2 or Wnt6, respectively. The media on these co-cultures of Wnt reporter and Wnt producer cells were replaced after 24 h to remove soluble Wnt ligands. After 48 h of co-culture, luciferase activity in cell extracts was measured with a kit from Promega.
For in vivo reporter assays, we generated a lentiviral vector containing the same transcription factor sites and minimal promoter as described above driving GFP expression. In addition, this vector contained a ubiquitous PGK promoter driving expression of a truncated human CD2 cDNA that allows identification of reportercontaining cells by FACS (Supplementary Fig. 29 ). Lentiviruses were generated in 293T cells using third-generation lentivirus packaging vectors, and virus particles were concentrated by ultracentrifugation. Freshly isolated tumour cells were infected with lentiviruses overnight, enriched by anti-CD2 MACS (Miltenyi) for cells carrying the reporter construct and orthotopically transplanted for tumour formation and spontaneous metastasis. Wnt signalling activity in cells of primary tumours or spontaneous pulmonary metastases was quantified by FACS analysis by measuring GFP 1 cells after gating for human-CD2 1 cells. Similarly, human-CD2 1 tumour cells were used for tumour mammosphere cultures to measure Wnt pathway activity in the presence or absence of the POSTN blocking antibody. Isolation of lung stromal cells. Lungs were minced with a razor blade and digested with a mixture of DNase and Liberase (Roche Diagnostics). On enzymatic digestion, samples were passed through a 100-mm filter and washed once in growth medium (DMEM/F12 with 2% FBS, 20 ng ml 21 EGF and 10 m ml 21 insulin; Invitrogen) and twice in PBS. Cells were plated onto plates pretreated with collagen and allowed to attach for three days. The medium was then changed to serum-free medium and tumour cells or soluble factors were added to test POSTN induction. POSTN expression was evaluated by western blot, PCR with reverse transcription or immunofluorescence analysis.
